Runda Medical(603108)2025-01-20 09:00Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 42.91 million and 51.49 million yuan, a decrease of 22.18 million to 23.04 million yuan compared to the previous year, representing a decline of 81.16% to 84.30%[5] - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between 21.97 million and 26.36 million yuan, down by 12.30 million to 12.74 million yuan year-on-year, reflecting a decrease of 82.36% to 85.29%[5] - The financial data in the performance forecast has not been audited by a registered accountant[6] - The forecast data is preliminary and subject to change, with the final audited financial data to be disclosed in the company's annual report for 2024[11] - The company emphasizes that there are no significant uncertainties affecting the accuracy of this performance forecast[10] Historical Financial Performance - In 2023, the company achieved a total profit of 655.56 million yuan, with a net profit attributable to shareholders of the parent company of 273.30 million yuan[8] - The company reported earnings per share of 0.47 yuan for the year 2023[8] Factors Affecting Profitability - The significant decrease in net profit is primarily due to the impact of domestic macroeconomic conditions and centralized procurement policies, which affected business development and sales revenue[9] - Fixed costs, such as service costs and depreciation of fixed assets, have not decreased, leading to increased marginal costs and expenses[9] - The collection period for accounts receivable from end customers has lengthened, resulting in credit impairment losses that significantly impacted the net profit attributable to shareholders of the parent company[9]